JP2024509251A - デュアルウイルスベクター系による抗体送達 - Google Patents

デュアルウイルスベクター系による抗体送達 Download PDF

Info

Publication number
JP2024509251A
JP2024509251A JP2023554927A JP2023554927A JP2024509251A JP 2024509251 A JP2024509251 A JP 2024509251A JP 2023554927 A JP2023554927 A JP 2023554927A JP 2023554927 A JP2023554927 A JP 2023554927A JP 2024509251 A JP2024509251 A JP 2024509251A
Authority
JP
Japan
Prior art keywords
antigen
viral vector
recombinant viral
chain
dual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023554927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509251A5 (https=
Inventor
ウェイミン ワン、
シアン ザン、
ヤンリン ミ、
ヂョンダオ リ、
クイング シャオ、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Jinsirui Science and Technology Biology Corp
Original Assignee
Nanjing Jinsirui Science and Technology Biology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Jinsirui Science and Technology Biology Corp filed Critical Nanjing Jinsirui Science and Technology Biology Corp
Publication of JP2024509251A publication Critical patent/JP2024509251A/ja
Publication of JP2024509251A5 publication Critical patent/JP2024509251A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023554927A 2021-03-08 2022-03-03 デュアルウイルスベクター系による抗体送達 Pending JP2024509251A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110252231.1 2021-03-08
CN202110252231 2021-03-08
PCT/CN2022/079047 WO2022188689A1 (zh) 2021-03-08 2022-03-03 使用双重病毒载体系统递送抗体

Publications (2)

Publication Number Publication Date
JP2024509251A true JP2024509251A (ja) 2024-02-29
JP2024509251A5 JP2024509251A5 (https=) 2025-03-11

Family

ID=83226363

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023554927A Pending JP2024509251A (ja) 2021-03-08 2022-03-03 デュアルウイルスベクター系による抗体送達

Country Status (6)

Country Link
US (1) US20240148903A1 (https=)
EP (1) EP4306131A4 (https=)
JP (1) JP2024509251A (https=)
KR (1) KR20230154074A (https=)
CN (1) CN116981485A (https=)
WO (1) WO2022188689A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118139628A (zh) * 2021-08-23 2024-06-04 阿维麦克思生物制药公司 用于转基因表达的组合物和方法
WO2025155774A2 (en) * 2024-01-19 2025-07-24 Amgen Inc. Vector engineering strategies to enhance volumetric productivity and decrease impurity formation across a diverse set of modalities
WO2025155776A1 (en) * 2024-01-19 2025-07-24 Amgen Inc. Expression vector systems with two copies of light chain

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050229275A1 (en) * 1998-10-30 2005-10-13 Thomas Jefferson University Production of biomedical peptides and proteins in plants using plant virus vectors
US20070224635A1 (en) * 2004-01-30 2007-09-27 Maxygen Holdings, Ltd. Regulated Stop Codon Readthrough
US20120258494A1 (en) * 2009-11-23 2012-10-11 4-Anitbody AG Retroviral Vector Particles and Methods for their Generation and Use
JP2015503907A (ja) * 2011-12-22 2015-02-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 真核細胞のための全長抗体提示システムおよびその使用
JP2015514811A (ja) * 2012-04-26 2015-05-21 バクシネックス インコーポレーティッド 特異的免疫グロブリン遺伝子組み換えワクシニアウイルスに感染している細胞の選択を容易にするための融合タンパク質

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
AU2001238079A1 (en) * 2000-02-09 2001-08-20 Med Immune, Inc. Antibody gene therapy with adeno-associated viral vectors
US7714119B2 (en) 2004-07-13 2010-05-11 Biosante Pharmaceuticals, Inc. AAV vector compositions and methods for enhanced expression of immunoglobulins using the same
CN101160055A (zh) * 2005-02-16 2008-04-09 莱蒂恩公司 慢病毒载体及其用途
US8865881B2 (en) 2011-02-22 2014-10-21 California Institute Of Technology Delivery of proteins using adeno-associated virus (AAV) vectors
US10093947B2 (en) 2012-02-28 2018-10-09 Cornell University AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
CN102634542B (zh) * 2012-04-12 2014-03-26 北京工业大学 一种表达人抗体全基因的重组腺相关病毒(rAAV)载体及其方法
US9828422B2 (en) 2013-07-29 2017-11-28 Samsung Electronics Co., Ltd. Anti-Ang2 antibody
EA201792500A1 (ru) 2015-05-13 2018-04-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Aav-опосредованная экспрессия антител против гриппа и способы их использования
WO2018129331A1 (en) 2017-01-07 2018-07-12 Merck Patent Gmbh Dosing regimens and dosage forms for targeted tgf-b inhibition
MY202480A (en) 2017-05-12 2024-04-30 Shanghai hengrui pharmaceutical co ltd Fusion protein containing tgf- receptor and medicinal uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050229275A1 (en) * 1998-10-30 2005-10-13 Thomas Jefferson University Production of biomedical peptides and proteins in plants using plant virus vectors
US20070224635A1 (en) * 2004-01-30 2007-09-27 Maxygen Holdings, Ltd. Regulated Stop Codon Readthrough
US20120258494A1 (en) * 2009-11-23 2012-10-11 4-Anitbody AG Retroviral Vector Particles and Methods for their Generation and Use
JP2015503907A (ja) * 2011-12-22 2015-02-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 真核細胞のための全長抗体提示システムおよびその使用
JP2015514811A (ja) * 2012-04-26 2015-05-21 バクシネックス インコーポレーティッド 特異的免疫グロブリン遺伝子組み換えワクシニアウイルスに感染している細胞の選択を容易にするための融合タンパク質

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BURTON M. ET AL.: "Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biological", PROC NATL ACAD SCI USA, vol. vol.96(22), JPN6026004957, 26 October 1999 (1999-10-26), pages 12725 - 12730, ISSN: 0005793345 *
PHOOLCHAROEN W. ET AL.: "Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana", PLANT BIOTECHNOL J, vol. vol.9(7), JPN6026004955, September 2011 (2011-09-01), pages 807 - 816, ISSN: 0005793344 *
SHANMUGARAJ B. ET AL.: "Monoclonal Antibodies B38 and H4 Produced in Nicotiana benthamiana Neutralize SARS-CoV-2 in vitro", FRONT PLANT SCI, vol. vol.11:589995, JPN6026004954, 27 November 2020 (2020-11-27), pages 1 - 11, ISSN: 0005793343 *
奥田 美香等: "血液凝固VIII 因子の構造と機能について", 血栓止血誌, vol. vol.2(51), JPN6026004956, 2014, pages 99 - 109, ISSN: 0005793346 *

Also Published As

Publication number Publication date
KR20230154074A (ko) 2023-11-07
EP4306131A1 (en) 2024-01-17
CN116981485A (zh) 2023-10-31
US20240148903A1 (en) 2024-05-09
EP4306131A4 (en) 2025-06-18
WO2022188689A1 (zh) 2022-09-15

Similar Documents

Publication Publication Date Title
CN117051045B (zh) 向性修饰的重组病毒载体及其用于将遗传材料靶向引入人细胞内的用途
JP2024509251A (ja) デュアルウイルスベクター系による抗体送達
US20190292250A1 (en) Aav-anti-vegf for treating cancer in companion animals
US20250354169A1 (en) Adeno-associated virus (aav) delivery of anti-fam19a5 antibodies
KR20250091321A (ko) 유전 물질을 인간 세포 내로 표적화하여 도입하기 위한 향성-변형 재조합 바이러스 입자 및 이의 용도
US12599680B1 (en) Treatments for ocular neovascularization
CN117587027A (zh) 编码抗vegf的抗体或抗原结合片段的多核苷酸表达盒及质粒
CA3228666A1 (en) Compositions and methods for transgene expression
US20260043046A1 (en) Cassettes of anti-complement component 3 antibody, vectorization and theraputic application
US20240216535A1 (en) Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
CN117587028A (zh) 编码抗vegf的抗体或抗原结合片段的多核苷酸表达盒及质粒
RU2811426C2 (ru) Рекомбинантные вирусные частицы с модифицированным тропизмом и пути их применения для нацеленного введения генетического материала в клетки человека
CN117070540A (zh) 编码抗vegf蛋白的多核苷酸表达盒、质粒及重组腺相关病毒
CN117070541A (zh) 编码抗vegf蛋白的多核苷酸表达盒、质粒及重组腺相关病毒
HK40097868A (zh) 用於治疗与血管生成相关的眼部疾病的组合物和方法
CN117343963A (zh) 核酸构建体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210